{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:12:14Z","timestamp":1793419934899,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Redox Biology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.redox.2026.104060","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:38:47Z","timestamp":1769531927000},"page":"104060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Are glutathionylated aldehyde reductases the missing piece of the \u201ccatecholaldehyde hypothesis\u201d in Parkinson's disease? A medical hypothesis concerning the detoxification of 4-hydroxynonenal (HNE) and 3,4-dihydroxyphenylacetaldehyde (DOPAL)"],"prefix":"10.1016","volume":"90","author":[{"given":"Rossella","family":"Rotondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"de Iure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Cocorocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Stocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilberto","family":"Stocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"de Pandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Picconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Issue 12","key":"10.1016\/j.redox.2026.104060_bib1","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.redox.2026.104060_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2013.10.027","article-title":"Early DEtection of wEaring off in Parkinson disease: the DEEP study","volume":"20","author":"Stocchi","year":"2014","journal-title":"Park. Relat. Disord."},{"issue":"Issue 6","key":"10.1016\/j.redox.2026.104060_bib3","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.redox.2026.104060_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-019-0332-6","article-title":"Impaired dopamine metabolism in Parkinson's disease pathogenesis","volume":"14","author":"Masato","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"3","key":"10.1016\/j.redox.2026.104060_bib5","doi-asserted-by":"crossref","DOI":"10.1046\/j.1471-4159.1999.0731127.x","article-title":"Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease","volume":"73","author":"Berman","year":"1999","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.redox.2026.104060_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2011.02.013","article-title":"Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease","volume":"1812","author":"Jana","year":"2011","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"3","key":"10.1016\/j.redox.2026.104060_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2007.11.007","article-title":"Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease","volume":"29","author":"van Laar","year":"2008","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.redox.2026.104060_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2010.03246.x","article-title":"Catechols in post-mortem brain of patients with Parkinson disease","volume":"18","author":"Goldstein","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.redox.2026.104060_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.2012.07924.x","article-title":"Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease","volume":"123","author":"Goldstein","year":"2012","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.redox.2026.104060_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/S0006-8993(00)02054-0","article-title":"Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment","volume":"861","author":"Fornai","year":"2000","journal-title":"Brain Res."},{"issue":"Issue 3","key":"10.1016\/j.redox.2026.104060_bib11","article-title":"Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders","volume":"144","author":"Goldstein","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.redox.2026.104060_bib12","article-title":"DOPAL initiates \u03b1Synuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson's disease","volume":"9","author":"Masato","year":"2023","journal-title":"npj Parkinson's Dis."},{"issue":"Issue 1","key":"10.1016\/j.redox.2026.104060_bib13","article-title":"Role of dopamine in the pathophysiology of Parkinson's disease","volume":"12","author":"Zhou","year":"2023","journal-title":"Transl. Neurodegener."},{"issue":"2","key":"10.1016\/j.redox.2026.104060_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S0006-8993(03)03354-7","article-title":"3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis","volume":"989","author":"Burke","year":"2003","journal-title":"Brain Res."},{"issue":"Issue 2","key":"10.1016\/j.redox.2026.104060_bib15","article-title":"Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase","volume":"59","author":"Marchitti","year":"2007","journal-title":"Pharmacol. Rev."},{"issue":"Issue 20","key":"10.1016\/j.redox.2026.104060_bib16","article-title":"Dopamine, oxidative stress and protein\u2013quinone modifications in parkinson's and other neurodegenerative diseases","volume":"58","author":"Monzani","year":"2019","journal-title":"Angew. Chem., Int. Ed."},{"issue":"6 I","key":"10.1016\/j.redox.2026.104060_bib17","article-title":"Molecular immunocytochemistry of the CuZn superoxide dismutase in rat hepatocytes","volume":"107","author":"Chang","year":"1988","journal-title":"JCB (J. Cell Biol.)"},{"issue":"30","key":"10.1016\/j.redox.2026.104060_bib18","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M111.249532","article-title":"Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone","volume":"286","author":"Anderson","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.redox.2026.104060_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.1989.tb11759.x","article-title":"A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra","volume":"53","author":"Saggu","year":"1989","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.redox.2026.104060_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s11064-010-0212-5","article-title":"The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease","volume":"35","author":"Baillet","year":"2010","journal-title":"Neurochem. Res."},{"issue":"2","key":"10.1016\/j.redox.2026.104060_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2008.03.031","article-title":"Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells","volume":"436","author":"Chae","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.redox.2026.104060_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuro.2018.06.005","article-title":"Aldehyde dehydrogenase 2 in the spotlight: the link between mitochondria and neurodegeneration","volume":"68","author":"Deza-Ponzio","year":"2018","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.redox.2026.104060_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.freeradbiomed.2016.08.015","article-title":"Human carbonyl reductase 1 as efficient catalyst for the reduction of glutathionylated aldehydes derived from lipid peroxidation","volume":"99","author":"Rotondo","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.redox.2026.104060_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2017.03.003","article-title":"Kinetic features of carbonyl reductase 1 acting on glutathionylated aldehydes","volume":"276","author":"Moschini","year":"2017","journal-title":"Chem. Biol. Interact."},{"issue":"10","key":"10.1016\/j.redox.2026.104060_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/antiox8100502","article-title":"Stereoselectivity of aldose reductase in the reduction of glutathionyl-hydroxynonanal adduct","volume":"8","author":"Balestri","year":"2019","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.redox.2026.104060_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/S0026-895X(25)13947-3","article-title":"Enzymatic reduction of \u201cbiogenic\u201d aldehydes in brain","volume":"9","author":"Tabakoff","year":"1973","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.redox.2026.104060_bib27","article-title":"Metabolism of aldehydes in brain","volume":"vol. 1","author":"Tipton","year":"1977"},{"key":"10.1016\/j.redox.2026.104060_bib28","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.pharmtox.47.120505.105316","article-title":"Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology","volume":"47","author":"Oppermann","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.redox.2026.104060_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(19)69950-3","article-title":"Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase","volume":"256","author":"Wermuth","year":"1981","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.redox.2026.104060_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/0006-2952(86)90271-6","article-title":"Carbonyl reductase provides the enzymatic basis of quinone detoxication in man","volume":"35","author":"Wermuth","year":"1986","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.redox.2026.104060_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007113","article-title":"Structural basis for substrate specificity in human monomeric carbonyl reductases","volume":"4","author":"Pilka","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.redox.2026.104060_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9378(80)90282-3","article-title":"Early steps in prostaglandin metabolism in the human placenta","volume":"138","author":"Jarabak","year":"1980","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.redox.2026.104060_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/j.1432-1033.1973.tb02958.x","article-title":"Heterogeneity of NADPH\u2010Dependent aldehyde reductase from human and rat brain","volume":"37","author":"Ris","year":"1973","journal-title":"Eur. J. Biochem."},{"issue":"8","key":"10.1016\/j.redox.2026.104060_bib34","doi-asserted-by":"crossref","DOI":"10.2174\/138920010794233530","article-title":"Human carbonyl reductases","volume":"11","author":"Mal\u00e1tkov\u00e1","year":"2010","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.redox.2026.104060_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-28383-8_19","article-title":"Detoxification of carbonyl compounds by carbonyl reductase in neurodegeneration","volume":"12","author":"Rashid","year":"2016","journal-title":"Adv. Neurobiol."},{"issue":"9","key":"10.1016\/j.redox.2026.104060_bib36","article-title":"Upregulation of carbonyl reductase 1 by Nrf2 as a potential therapeutic intervention for ischemia\/reperfusion injury during liver transplantation","volume":"42","author":"Kwon","year":"2019","journal-title":"Mol. Cells"},{"issue":"5","key":"10.1016\/j.redox.2026.104060_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s12975-021-00912-6","article-title":"Carbonyl reductase 1 attenuates ischemic brain injury by reducing oxidative stress and neuroinflammation","volume":"12","author":"Mao","year":"2021","journal-title":"Transl. Stroke Res."},{"key":"10.1016\/j.redox.2026.104060_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.freeradbiomed.2015.02.001","article-title":"NADP+-dependent dehydrogenase activity of carbonyl reductase on glutathionylhydroxynonanal as a new pathway for hydroxynonenal detoxification","volume":"83","author":"Moschini","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.redox.2026.104060_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.freeradbiomed.2014.01.006","article-title":"Neuroprotective effects of PEP-1-carbonyl reductase 1 against oxidative-stress-induced ischemic neuronal cell damage","volume":"69","author":"Kim","year":"2014","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.redox.2026.104060_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2005.12.113","article-title":"Neuroprotective role for carbonyl reductase?","volume":"340","author":"Maser","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.redox.2026.104060_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-018-0942-9","article-title":"Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma","volume":"37","author":"Yun","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.redox.2026.104060_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2010.06.045","article-title":"Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells","volume":"54","author":"Tak","year":"2011","journal-title":"J. Hepatol."},{"issue":"16","key":"10.1016\/j.redox.2026.104060_bib43","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-12-1110","article-title":"Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide","volume":"72","author":"Jang","year":"2012","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.redox.2026.104060_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2013.05.025","article-title":"Carbonyl reductase 1 is an essential regulator of skeletal muscle differentiation and regeneration","volume":"45","author":"Lim","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"4","key":"10.1016\/j.redox.2026.104060_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2006.08.005","article-title":"Reactive oxygen species modulate the differentiation of neurons in clonal cortical cultures","volume":"33","author":"Tsatmali","year":"2006","journal-title":"Mol. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.redox.2026.104060_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.devcel.2019.05.011","article-title":"Redox signaling via lipid peroxidation regulates retinal progenitor cell differentiation","volume":"50","author":"Albadri","year":"2019","journal-title":"Dev. Cell"},{"issue":"41","key":"10.1016\/j.redox.2026.104060_bib47","doi-asserted-by":"crossref","DOI":"10.1021\/bi049136q","article-title":"Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal","volume":"43","author":"Doorn","year":"2004","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.redox.2026.104060_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphs.2017.09.001","article-title":"Prostaglandin E2 facilitates neurite outgrowth in a motor neuron-like cell line, NSC-34","volume":"135","author":"Nango","year":"2017","journal-title":"J. Pharmacol. Sci."},{"issue":"1\u20133","key":"10.1016\/j.redox.2026.104060_bib49","article-title":"Regulation of human carbonyl reductase 1 (CBR1, SDR21C1) gene by transcription factor Nrf2","volume":"202","author":"Miura","year":"2013","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"10.1016\/j.redox.2026.104060_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-025-08564-0","article-title":"Vitamin K2 inhibits PGE2-mediated osteoblast ferroptosis by upregulation of CBR1 via the Nrf2\/Keap1 pathway","volume":"8","author":"Tao","year":"2025","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.redox.2026.104060_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-018-0942-9","article-title":"Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma","volume":"37","author":"Yun","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.redox.2026.104060_bib52","article-title":"Upregulation of carbonyl reductase 1 by Nrf2 as a potential therapeutic intervention for Ischemia\/reperfusion injury during liver transplantation","volume":"42","author":"Kwon","year":"2019","journal-title":"Mol. Cell"},{"issue":"28","key":"10.1016\/j.redox.2026.104060_bib53","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M909235199","article-title":"Kinetic and structural characterization of the glutathione-binding site of aldose reductase","volume":"275","author":"Dixit","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.redox.2026.104060_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/0891-5849(91)90192-6","article-title":"Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes","volume":"11","author":"Esterbauer","year":"1991","journal-title":"Free Radic. Biol. Med."},{"issue":"Issue 2","key":"10.1016\/j.redox.2026.104060_bib55","article-title":"The mercapturomic profile of health and non-communicable diseases","volume":"8","author":"Gon\u00e7alves-Dias","year":"2019","journal-title":"High-Throughput"},{"issue":"Issue 10","key":"10.1016\/j.redox.2026.104060_bib56","article-title":"The mercapturic acid pathway","volume":"49","author":"Hanna","year":"2019","journal-title":"Crit. Rev. Toxicol."},{"issue":"3","key":"10.1016\/j.redox.2026.104060_bib57","doi-asserted-by":"crossref","DOI":"10.1021\/tx025671k","article-title":"Identification of intermediate pathways of 4-hydroxynonenal metabolism in the rat","volume":"16","author":"Alary","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.redox.2026.104060_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.freeradbiomed.2017.01.036","article-title":"Enzymatic and non-enzymatic detoxification of 4-hydroxynonenal: methodological aspects and biological consequences","volume":"111","author":"Mol","year":"2017","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.redox.2026.104060_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/0271678X18808399","article-title":"Mechanisms of glutathione-conjugate efflux from the brain into blood: involvement of multiple transporters in the course","volume":"40","author":"Okamura","year":"2020","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"5","key":"10.1016\/j.redox.2026.104060_bib60","doi-asserted-by":"crossref","DOI":"10.1021\/tx800405v","article-title":"Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate","volume":"22","author":"Jinsmaa","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.redox.2026.104060_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.freeradbiomed.2013.05.001","article-title":"Glutathione metabolism and Parkinson's disease","volume":"62","author":"Smeyne","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.redox.2026.104060_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2016.07.009","article-title":"Elevated cerebrospinal fluid ratios of cysteinyl-dopamine\/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies","volume":"31","author":"Goldstein","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.redox.2026.104060_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuro.2021.07.005","article-title":"In vitro inhibition of glutathione-S-transferase by dopamine and its metabolites, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid","volume":"86","author":"Crawford","year":"2021","journal-title":"Neurotoxicology"},{"issue":"11","key":"10.1016\/j.redox.2026.104060_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/jms.533","article-title":"Detoxification of 4-hydroxynonenal (HNE) in keratinocytes: characterization of conjugated metabolites by liquid chromatography\/electrospray ionization tandem mass spectrometry","volume":"38","author":"Aldini","year":"2003","journal-title":"J. Mass Spectrom."},{"issue":"2","key":"10.1016\/j.redox.2026.104060_bib65","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.115.230201","article-title":"Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells","volume":"356","author":"Goldstein","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.redox.2026.104060_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2018.02.023","article-title":"Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease","volume":"50","author":"Goldstein","year":"2018","journal-title":"Park. Relat. Disord."},{"issue":"15","key":"10.1016\/j.redox.2026.104060_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512522","article-title":"Dihydroxyphenylacetaldehyde lowering treatment improves locomotor and neurochemical abnormalities in the rat rotenone model: relevance to the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease","volume":"24","author":"Khashab","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.redox.2026.104060_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104514","article-title":"5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: implications for Parkinson's disease","volume":"129","author":"Badillo-Ram\u00edrez","year":"2019","journal-title":"Neurochem. Int."},{"issue":"Issue 4","key":"10.1016\/j.redox.2026.104060_bib69","article-title":"Are dopamine oxidation metabolites involved in the loss of dopaminergic neurons in the nigrostriatal system in parkinson's disease?","volume":"8","author":"Herrera","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"6","key":"10.1016\/j.redox.2026.104060_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.12686","article-title":"Protective and toxic roles of dopamine in Parkinson's disease","volume":"129","author":"Segura-Aguilar","year":"2014","journal-title":"J. Neurochem."},{"issue":"11","key":"10.1016\/j.redox.2026.104060_bib71","doi-asserted-by":"crossref","DOI":"10.1007\/s11064-017-2371-0","article-title":"N-Acetylcysteine prevents the increase in spontaneous oxidation of dopamine during monoamine oxidase inhibition in PC12 cells","volume":"42","author":"Goldstein","year":"2017","journal-title":"Neurochem. Res."},{"issue":"5","key":"10.1016\/j.redox.2026.104060_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2015.02.020","article-title":"Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson's disease","volume":"21","author":"Katz","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.redox.2026.104060_bib73","doi-asserted-by":"crossref","DOI":"10.1097\/WNF.0b013e31829ae713","article-title":"N-acetylcysteine boosts brain and blood glutathione in gaucher and Parkinson diseases","volume":"36","author":"Holmay","year":"2013","journal-title":"Clin. Neuropharmacol."},{"issue":"11","key":"10.1016\/j.redox.2026.104060_bib74","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024411","article-title":"Modeling the progression of cardiac catecholamine deficiency in lewy body diseases","volume":"11","author":"Goldstein","year":"2022","journal-title":"J. Am. Heart Assoc."}],"container-title":["Redox Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231726000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231726000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:47:58Z","timestamp":1785858478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213231726000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":74,"alternative-id":["S2213231726000583"],"URL":"https:\/\/doi.org\/10.1016\/j.redox.2026.104060","relation":{},"ISSN":["2213-2317"],"issn-type":[{"value":"2213-2317","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are glutathionylated aldehyde reductases the missing piece of the \u201ccatecholaldehyde hypothesis\u201d in Parkinson's disease? A medical hypothesis concerning the detoxification of 4-hydroxynonenal (HNE) and 3,4-dihydroxyphenylacetaldehyde (DOPAL)","name":"articletitle","label":"Article Title"},{"value":"Redox Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.redox.2026.104060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104060"}}